Enliven Therapeutics (ELVN) EBITDA (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of EBITDA data on file, last reported at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 12.21% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$115.8 million (down 5.01% YoY), and the FY2025 full-year result was -$119.7 million, down 14.45% from the prior year.
• EBITDA climbed to -$27.8 million in Q1 2026, from -$34.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.7 million in Q1 2022 to a low of -$34.3 million in Q4 2025.
• A 5-year average of -$22.0 million and a median of -$24.6 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 31.54% in 2022 and sank 123.64% in 2023, its largest moves.
• Tracing ELVN's EBITDA over 5 years: stood at -$10.2 million in 2022, then plunged by 123.64% to -$22.7 million in 2023, then slipped by 18.33% to -$26.9 million in 2024, then slipped by 27.47% to -$34.3 million in 2025, then increased by 18.85% to -$27.8 million in 2026.
• Business Quant data shows ELVN's EBITDA at -$27.8 million in Q1 2026, -$34.3 million in Q4 2025, and -$25.1 million in Q3 2025.